Expression and/or Activity of the SVCT2 Ascorbate Transporter May be Decreased in Many Aggressive Cancers, Suggesting Potential Utility for Sodium Bicarbonate and Dehydroascorbic Acid in Cancer Therapy

Within cancer cells, vitamin C (ascorbate) performs the key function of controlling the activity of hypoxia-inducible factor-1 (HIF-1), a protein which helps cancer cells to thrive in low oxygen conditions and makes them much more aggressive. But there is evidence that in at least some cancers, their ascorbate content is too low to optimally control HIF-1 activity – and unfortunately simply ingesting more vitamin C is unlikely to correct the problem. However, the vitamin C metabolite dehydroascorbic acid can get into cancer cells efficiently – and once inside the cell is rapidly converted to ascorbate. So it is proposed that regular intravenous infusions of dehydroascorbic acid could be employed to optimize the ascorbate content of cancers, and thereby help control their aggressiveness.

Click to download